Loss of exclusivitySeptember 2040latest FDA-listed patent expiry
Companymedicines360 →See this company's full patent-cliff portfolio
Drug detail
Brand name
LILETTA
Active ingredient
LEVONORGESTREL
Strength
52MG
Dosage form
SYSTEM
Route
INTRAUTERINE
Modality
Small molecule
FDA approval
February 2015
Marketing status
RX
Listed patents
Patent
Expires
Type
11571328
September 2040
product
10028858
March 2034
product
11090186
October 2033
use U-2348
12004992
October 2033
substance
Regulatory exclusivity
Code
Expires
I-917
June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.
LILETTA patent cliff — loss of exclusivity September 2040 | CliffBio